Sab Biotherapeutics Stock Piotroski F Score

SABSW Stock  USD 0.07  0.01  9.12%   
This module uses fundamental data of SAB Biotherapeutics to approximate its Piotroski F score. SAB Biotherapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of SAB Biotherapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about SAB Biotherapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out SAB Biotherapeutics Altman Z Score, SAB Biotherapeutics Correlation, SAB Biotherapeutics Valuation, as well as analyze SAB Biotherapeutics Alpha and Beta and SAB Biotherapeutics Hype Analysis.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.
  
At this time, SAB Biotherapeutics' Long Term Debt is fairly stable compared to the past year. Net Debt To EBITDA is likely to climb to 1.40 in 2024, despite the fact that Net Debt is likely to grow to (48.1 M). At this time, SAB Biotherapeutics' Net Debt To EBITDA is fairly stable compared to the past year. Current Ratio is likely to climb to 5.72 in 2024, whereas Book Value Per Share is likely to drop 7.50 in 2024.
At this time, it appears that SAB Biotherapeutics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Increase

Focus
Long Term Debt Over Assets Change

Higher Leverage

Focus
Change In Outstending Shares

Increase

Focus
Change in Gross Margin

Increase

Focus

SAB Biotherapeutics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to SAB Biotherapeutics is to make sure SAB is not a subject of accounting manipulations and runs a healthy internal audit department. So, if SAB Biotherapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if SAB Biotherapeutics' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.02530.0267
Notably Down
Pretty Stable
Total Current Liabilities14.6 M10.8 M
Significantly Up
Slightly volatile
Non Current Liabilities Total9.4 M15.8 M
Way Down
Slightly volatile
Total Assets63.5 M83.9 M
Way Down
Slightly volatile
Total Current Assets38.1 M58.9 M
Way Down
Slightly volatile

SAB Biotherapeutics F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between SAB Biotherapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards SAB Biotherapeutics in a much-optimized way.

About SAB Biotherapeutics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

7.5

At this time, SAB Biotherapeutics' Book Value Per Share is fairly stable compared to the past year.

About SAB Biotherapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.